On April 19, 2022 Panolos Biosciences reported the results of anti-cancer research of its main pipeline, PB101, at the AACR (Free AACR Whitepaper) Annual Meeting 2022 held from the 8th (local time) to the 13th (Press release, Panolos Bioscience, APR 19, 2022, View Source [SID1234633689]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PB101 is an anti-cancer drug developed by Panolos and being jointly researched by Professor Hong-Jae Jeon and Chan Kim’s team at the Department of Hematology and Oncology at CHA Bundang Hospital. It has a mechanism to inhibit the growth of cancer cells by targeting all types of vascular endothelial growth factors (VEGF-A, VEGF-B, Placental Growth Factor) that are excessively produced around cancer cells.
According to the non-clinical results presented by Panolos at this AACR (Free AACR Whitepaper), PB101 not only inhibits tumor growth by blocking intratumoral angiogenesis, but also increases tumor-hostile immune cells by influencing the immune environment in the tumor microenvironment. appear. In addition, the excellent antitumor effect and survival rate were confirmed through an experiment of combination administration of PB101 with an immuno-anticancer drug, and unlike the single administration experiment group, 27.2% of subjects in the combination administration experiment group showed a complete remission effect.
In an experiment to confirm growth and lung metastasis through repetitive tumor engraftment on subjects who showed complete remission, it was confirmed that, unlike the control group, cancer did not grow. This is due to the formation of memory immune cells that remember the tumor cell line during the combination treatment process. It is estimated that it did.
Based on the results presented at this AACR (Free AACR Whitepaper), Panolos hopes that PB101’s inhibitory effect on angiogenesis in tumors and its immune-activating effect can create a synergistic effect when used in combination with existing immuno-cancer drugs, providing new treatment options to patients. is looking forward to PB101 aims to apply for a phase 1 clinical trial approval (IND) within this year.